ESLA
NASDAQEstrella Immunopharma Inc.
Estrella Immunopharma Inc. (ESLA) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for ESLA, including 2 press releases and news items, 1 leadership change and 1 SEC filing. The most recent was published Nov 3, 2026.
Financial highlights
Full financials- Net income, TTM
- -$10.01M
- Cash
- $100.0K
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks19+100%
2026-05-102026-11-01
Mix1190d
- SEC Filings4(36%)
- Other3(27%)
- Insider3(27%)
- Leadership1(9%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Pussinen Cynthia3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
- SECSEC Form 8-K filed by Estrella Immunopharma Inc.8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
- PREstrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of DirectorsAn accomplished biotechnology executive, Ms. Pussinen brings more than 30 years of global leadership experience spanning advanced therapies, clinical development, commercialization, strategic partnerships and capital formation Appointment comes at a pivotal stage as Estrella advances its differentiated ARTEMIS® T-cell therapy platform for cancer and autoimmune diseases Cheng Liu, Ph.D., appointed Chief Scientific Officer; continues as President and as a member of the Board of Directors Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS® T-cell therapies for the treatment of cancer and a
- PREstrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion PhasePatient received two infusions three weeks apart at the recommended Phase II dose; no treatment-related serious adverse events observed through the first month of follow-up Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced that the first patient who received two infusions, each at 5 × 10⁶ EB103 T cells/kg, three weeks apart, in the dose-expansion phase has tolerated the study drug well in the first month, with no treatment-related serious adverse events (SAEs) reported. STARLIGHT-1 is evaluating EB103, Estr
- PREstrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaEstrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the activation of a fifth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating its investigational product candidate EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, Intermountain Health LDS Hospital, in Salt Lake City, Utah, is expected to begin screening and enrolling patients following completion of site initiation activities."I
- SECEstrella Immunopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
- INSIDERCEO Liu Cheng exercised 100,000 shares at a strike of $0.81, increasing direct ownership by 34% to 397,437 units (SEC Form 4)4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
- INSIDERChief Financial Officer Xu Jiandong exercised 100,000 shares at a strike of $0.81, increasing direct ownership by 38% to 365,488 units (SEC Form 4)4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
- SECEstrella Immunopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Estrella Immunopharma Inc.SCHEDULE 13G/A - Estrella Immunopharma, Inc. (0001844417) (Subject)
- SECSEC Form 10-Q filed by Estrella Immunopharma Inc.10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)
- PREstrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaEstrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a third clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory ("R/R") B-cell non-Hodgkin’s lymphoma ("NHL"). The new site, Oregon Health & Science University in Portland, Oregon, has begun screening and enrolling patients."The activation of Oregon Health & Science University, a leading academic medical center, reflects the continued
- PREstrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaEstrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory ("R/R") B-cell non-Hodgkin’s lymphoma ("NHL"). The new site, Baylor Research Institute d/b/a Baylor Scott & White Research Institute in Dallas, Texas, has begun screening and enrolling patients."Partnering with Baylor Scott & White Research Institute, a nationally recogn
- PREstrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s LymphomaEstrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). Estrella’s dosing of the first patient in the dose-expansion cohort follows encouraging efficacy data from the dose-escalation cohort. At the 6-month assessment of evaluable Phase I patients
- SECEstrella Immunopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECSEC Form DEF 14A filed by Estrella Immunopharma Inc.DEF 14A - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECSEC Form 10-Q filed by Estrella Immunopharma Inc.10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECSEC Form NT 10-Q filed by Estrella Immunopharma Inc.NT 10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)
- SECSEC Form SCHEDULE 13G filed by Estrella Immunopharma Inc.SCHEDULE 13G - Estrella Immunopharma, Inc. (0001844417) (Subject)
- PREstrella Immunopharma to Participate in the D. Boral Capital Global ConferenceEstrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerging-growth public and private companies to engage directly with institutional investors and strategic partners. Date: May 7, 2026 Venue: The Plaza Hotel, New York, NY Website: https://dboralcapital.com/conference Investors interest
- SECAmendment: SEC Form 10-K/A filed by Estrella Immunopharma Inc.10-K/A - Estrella Immunopharma, Inc. (0001844417) (Filer)
- INSIDERChief Financial Officer Xu Jiandong bought $2,594 worth of shares (2,100 units at $1.24), increasing direct ownership by 0.38% to 265,488 units (SEC Form 4)4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
- PREstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap ResearchEstrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company's differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. "The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical compani
- SECSEC Form 424B3 filed by Estrella Immunopharma Inc.424B3 - Estrella Immunopharma, Inc. (0001844417) (Filer)
- PREstrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). The oral presentation highlighted clinical data from the Company's ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the ST
ESLA FAQ
8 questionsWhat is the latest news on ESLA?
In the last 30 days Quantisnow tracked 5 wire items for ESLA: 2 press releases and news items, 1 leadership change, 1 SEC filing and 1 insider trade. The most recent was published on November 3, 2026.Is ESLA profitable?
No. Estrella Immunopharma Inc. reported a net loss of $10.01M for the twelve months ended Jun 30, 2026.How much cash and debt does ESLA have?
Estrella Immunopharma Inc. reported $100.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ESLA stock trade?
Estrella Immunopharma Inc. (ESLA) is listed on NASDAQ.What sector and industry is ESLA in?
Estrella Immunopharma Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Estrella Immunopharma Inc. go public?
Estrella Immunopharma Inc. (ESLA) completed its IPO in 2021.What companies are similar to ESLA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ESLA side-by-side with any of them on Quantisnow.How can I track ESLA on Quantisnow?
Quantisnow aggregates Estrella Immunopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ESLA to receive live email and push alerts on every new disclosure.